Lutetium Oxodotreotide

Phase 2Radiopharmaceutical

Lutetium Oxodotreotide is one of 80 small molecule programs targeting Pancreatic Neuroendocrine Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Neuroendocrine TumorActive, not recruiting

Neuroendocrine NeoplasmActive, not recruiting

Pancreatic Neuroendocrine TumorPhase 2

Active, not recruiting

Neuroendocrine NeoplasmPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

60 competitors in Pancreatic Neuroendocrine Tumor

#DrugCompanyPhaseTrials

DTIC-Dome

Afinitor

8 3

Glucophage

Sandostatin

Octreotide

Sutent

5 7

FOLFOX

AstraZeneca

Phase 3

1 8

Cabometyx

Bristol-Myers Squibb

Phase 2

1 9

Thalomid

Bristol-Myers Squibb

Phase 2

1 10

Ibrance

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Treatment

NCT05459844

Q2 2029

Phase 2/3Active, not recruiting

Neuroendocrine Neoplasm

NCT06398444

Clinical

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Active, not recruiting·SSinotau Pharmaceutical Group·Phase 2/3·NCT06398444·74 enrolled

Pancreatic Neuroendocrine Tumor1 trial

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Not yet recruiting·PPeking University·Phase 2·NCT05894486·40 enrolled

Treatment1 trial

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruiting·SSinotau Pharmaceutical Group·Phase 3·NCT05459844·196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lutetium Oxodotreotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutetium Oxodotreotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutetium Oxodotreotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinotau Pharmaceutical Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 2[1]
Company: SSinotau Pharmaceutical Group

Lutetium Oxodotreotide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Neuroendocrine Neoplasm1 trial

Pancreatic Neuroendocrine Tumor1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News